Like many diseases, atherosclerotic cardiovascular disease is driven by the activity of inflammatory cells. Using molecular imaging to target and analyze populations of inflammatory cells is one promising strategy to non-invasively assess atherosclerosis progression. However, current molecular imaging contrast agents are not suited for such targeted imaging applications. Nanomaterial-based strategies...